Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma

Acta Haematol. 2001;106(3):141-2. doi: 10.1159/000046607.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Carboplatin / administration & dosage
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Ifosfamide / administration & dosage
  • Immunologic Factors / therapeutic use*
  • Immunotherapy*
  • Interferon-alpha / therapeutic use*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoplasm Recurrence, Local / therapy
  • Prednisone / administration & dosage
  • Radiotherapy, Adjuvant
  • Remission Induction
  • Rituximab
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Interferon-alpha
  • Cytarabine
  • Bleomycin
  • Rituximab
  • Vincristine
  • Etoposide
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin
  • Ifosfamide
  • Prednisone
  • Methotrexate

Supplementary concepts

  • ICE protocol 2
  • PROMACE-CytaBOM protocol